Literature DB >> 10997931

Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan.

A Nishino1, Y Kato, T Igarashi, Y Sugiyama.   

Abstract

Canalicular multispecific organic anion transporter (cMOAT/MRP2) is known to play a major role in the transport of anionic xenobiotics including many types of glucuronide and glutathione conjugates across the bile canalicular membrane. In the present study, the biliary excretion of telmisartan (BIBR 277) and its glucuronide was examined in Sprague-Dawley rats (SDRs) and also in mutant strain Eisai-hyperbilirubinemic rats (EHBR), which have a hereditary defect in cMOAT/MRP2. Only a minimal difference was observed in the time profile of the plasma concentration of total radioactivity after administration of an i.v. bolus of BIBR 277. About 45% of the administered dose was excreted into bile up to 240 min in both strains, most of the radioactivity in the bile being BIBR 277 glucuronide. No significant difference was observed in the biliary excretion of BIBR 277 and its glucuronide between SDRs and EHBR although the plasma disappearance of BIBR 277 glucuronide was delayed in EHBR. To explain these data, the extent of glucuronidation of BIBR 277 by liver microsomes was examined in both strains. The V(max) value for the formation of BIBR 277 glucuronide was 2 to 3 times higher in EHBR than in SDRs, whereas both strains had similar K(m) values. After an i.v. bolus administration of BIBR 277 glucuronide, its plasma disappearance was delayed in EHBR, the biliary clearance in EHBR being about half that in SDRs. These results suggest that BIBR 277 glucuronide is transported by both cMOAT/MRP2 and another transporter that is also expressed in EHBR, and that the BIBR 277 glucuronidation is enhanced in EHBR, resulting in comparable excretion of glucuronide in both strains.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997931

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Dynamic analysis of GI absorption and hepatic distribution processes of telmisartan in rats using positron emission tomography.

Authors:  Makoto Kataoka; Tadayuki Takashima; Tomotaka Shingaki; Yoshinobu Hashidzume; Yumiko Katayama; Yasuhiro Wada; Hiroyuki Oh; Yoshie Masaoka; Shinji Sakuma; Yuichi Sugiyama; Shinji Yamashita; Yasuyoshi Watanabe
Journal:  Pharm Res       Date:  2012-05-23       Impact factor: 4.200

Review 3.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Effect of Cryopreservation on Enzyme and Transporter Activities in Suspended and Sandwich Cultured Rat Hepatocytes.

Authors:  Janneke Keemink; Neel Deferm; Tom De Bruyn; Patrick Augustijns; Thomas Bouillon; Pieter Annaert
Journal:  AAPS J       Date:  2018-02-21       Impact factor: 4.009

5.  Effects of UGT1A1 Polymorphism, Gender and Triglyceride on the Pharmacokinetics of Telmisartan in Chinese Patients with Hypertension: A Population Pharmacokinetic Analysis.

Authors:  Lu Huang; Liu Yang; Jie Huang; Hong-Yi Tan; Shi-Kun Liu; Cheng-Xian Guo; Xiao-Cong Zuo; Guo-Ping Yang; Qi Pei
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-12       Impact factor: 2.441

6.  Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.

Authors:  Cuiping Chen; Dennis Scott; Elizabeth Hanson; Judy Franco; Edwin Berryman; Mario Volberg; Xingrong Liu
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

7.  CM2 antigen, a potential novel molecule participating in glucuronide transport on rat hepatocyte canalicular membrane.

Authors:  L Wang; J Wang; X Zhou; J Li; Y Shi; Z Han; X Wang; S Li; Z Yang; R Wang; D Fan; Y Han
Journal:  Eur J Histochem       Date:  2012-06-29       Impact factor: 3.188

8.  Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.

Authors:  Wang-Qing Chen; Yan Shu; Qing Li; Lin-Yong Xu; Mary W Roederer; Lan Fan; Lan-Xiang Wu; Fa-Zhong He; Jian-Quan Luo; Zhi-Rong Tan; Yi-Jing He; Hong-Hao Zhou; Xiang Chen; Wei Zhang
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.